Ga68 PET Scan

NETSPOT®

Health Canada has approved NETSPOT® (kit for the preparation of gallium (68Ga) oxodotreotide injection) for the evaluation of neuroendocrine tumours (“NETs”). NETSPOT® is the first and only kit for the preparation of gallium (68Ga) oxodotreotide injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastroenteropancreatic neuroendocrine tumours (GEPNET) for localizing primary tumours and their metastases.

Gallium (68Ga) oxodotreotide injection

NETSPOT® (kit for the preparation of gallium (68Ga) oxodotreotide injection)
PRODUCT MONOGRAPH (ENG)
PRODUCT MONOGRAPH (FRE)
Brand Name NETSPOT®
Generic Name kit for the preparation of gallium (68Ga) oxodotreotide injection
Dosage In adult patients – The recommended amount of radioactivity to be administered for PET imaging is up to  2 MBq/kg of body weight (0.054 mCi/kg) up to 200 MBq (5.4 mCi).
Indication NETSPOT® [kit for the preparation of gallium (68Ga) oxodotreotide injection], after radiolabeling with gallium (68Ga), is indicated for use with positron emission tomography (PET), as an adjunct to other diagnostic tests for localization of somatostatin receptor-positive neuroendocrine tumors (NETs).
Tumour Type NETs
Contraindications None

Access to NETSPOT®

Health Canada Approval of NETSPOT – PRESS RELEASE

NETSPOT® – Health Canada Approved and Now Available.  Kit for the preparation of gallium (68Ga) oxodotreotide injection

Advanced Accelerator Applications S.A. (AAA), a Novartis company is pleased to announce that Health Canada has approved NETSPOT® (kit for the preparation of gallium (68Ga) oxodotreotide injection).

INDICATION

NETSPOT® [kit for the preparation of gallium (68Ga) oxodotreotide injection], after radiolabeling with gallium (68Ga), is indicated for use with positron emission tomography (PET), as an adjunct to other diagnostic tests for localization of somatostatin receptor-positive neuroendocrine tumors (NETs).

FOR MORE INFORMATION:

Please consult the Product Monograph at https://www.adacap.com/our-products/ for important product information relating to dosing information, drug interactions and adverse reactions. The Product Monograph is also available by calling AAA Customer Service at Tel: 1-844-367-3222.

Access to NETSPOT® in Canada